LIAN vs. PHXM, PLUR, NUTX, CODX, AKLI, RPID, GBS, AWH, BCLI, and SPRB
Should you be buying LianBio stock or one of its competitors? The main competitors of LianBio include PHAXIAM Therapeutics (PHXM), Pluri (PLUR), Nutex Health (NUTX), Co-Diagnostics (CODX), Akili (AKLI), Rapid Micro Biosystems (RPID), GBS (GBS), Aspira Women's Health (AWH), Brainstorm Cell Therapeutics (BCLI), and Spruce Biosciences (SPRB). These companies are all part of the "medical" sector.
PHAXIAM Therapeutics (NASDAQ:PHXM) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.
LianBio received 4 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users.
PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
LianBio has a consensus target price of $5.33, indicating a potential upside of 1,510.35%. Given PHAXIAM Therapeutics' higher probable upside, analysts plainly believe LianBio is more favorable than PHAXIAM Therapeutics.
In the previous week, LianBio had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for LianBio and 2 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.49 beat LianBio's score of 0.00 indicating that LianBio is being referred to more favorably in the news media.
PHAXIAM Therapeutics has higher revenue and earnings than LianBio.
0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
LianBio's return on equity of 0.00% beat PHAXIAM Therapeutics' return on equity.
Summary
LianBio beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.
Get LianBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
